These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. Jeong SH; Kim SY; Huh HJ; Ki CS; Lee NY; Kang CI; Chung DR; Peck KR; Shin SJ; Koh WJ Int J Infect Dis; 2017 Jul; 60():49-56. PubMed ID: 28522316 [TBL] [Abstract][Full Text] [Related]
8. Impact on Macrolide Resistance of Genetic Diversity of Mycobacterium abscessus Species. Jong BE; Wu TS; Chen NY; Yang CH; Shu CC; Wang LS; Wu TL; Lu JJ; Chiu CH; Lai HC; Chung WH Microbiol Spectr; 2022 Dec; 10(6):e0274922. PubMed ID: 36416559 [TBL] [Abstract][Full Text] [Related]
9. Association between sequevar and antibiotic treatment outcome in patients with Mycobacterium abscessus complex infections in Japan. Yoshida S; Tsuyuguchi K; Kobayashi T; Tomita M; Inoue Y; Hayashi S; Suzuki K J Med Microbiol; 2018 Jan; 67(1):74-82. PubMed ID: 29227218 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. Lee MC; Sun PL; Wu TL; Wang LH; Yang CH; Chung WH; Kuo AJ; Liu TP; Lu JJ; Chiu CH; Lai HC; Chen NY; Yang JH; Wu TS J Antimicrob Chemother; 2017 Oct; 72(10):2782-2786. PubMed ID: 29091186 [TBL] [Abstract][Full Text] [Related]
11. Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. Cho EH; Huh HJ; Song DJ; Lee SH; Kim CK; Shin SY; Ki CS; Jhun BW; Moon SM; Kwon OJ; Koh WJ; Lee NY Diagn Microbiol Infect Dis; 2019 Feb; 93(2):107-111. PubMed ID: 30236529 [TBL] [Abstract][Full Text] [Related]
12. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates]. Sürücüoğlu S; Özkütük N; Gazi H; Çavuşoğlu C Mikrobiyol Bul; 2023 Oct; 57(4):639-649. PubMed ID: 37885391 [TBL] [Abstract][Full Text] [Related]
13. Investigating the role of Yusuf B; Wang S; Alam MS; Zhang J; Liu Z; Lu Z; Ding J; Chiwala G; Gao Y; Fang C; Khan SA; Tian X; Islam MM; Hameed HMA; Maslov DA; Zhong N; Hu J; Zhang T Microbiol Spectr; 2024 Oct; 12(10):e0397423. PubMed ID: 39162545 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of Intermittent Multidrug IV Therapy for Refractory Mycobacterium abscessus Pulmonary Disease. Im Y; Kim SY; Kim DH; Jhun BW Chest; 2024 Feb; 165(2):288-302. PubMed ID: 37661004 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial peptides against drug resistant Mycobacterium abscessus. da Silva JL; Gupta S; Olivier KN; Zelazny AM Res Microbiol; 2020; 171(5-6):211-214. PubMed ID: 32198075 [TBL] [Abstract][Full Text] [Related]
16. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792 [TBL] [Abstract][Full Text] [Related]
17. [A pharmacologic approach to treatment of Mycobacterium abscessus pulmonary disease]. Kassegne L; Veziris N; Fraisse P Rev Mal Respir; 2024 Jan; 41(1):29-42. PubMed ID: 38016833 [TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Dousa KM; Shin E; Kurz SG; Plummer M; Nantongo M; Bethel CR; Taracila MA; Nguyen DC; Kreiswith BN; Daley CL; Remy KE; Holland SM; Bonomo RA mBio; 2024 Jun; 15(6):e0060924. PubMed ID: 38742824 [TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease. Choi H; Kim SY; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin S; Shin SJ; Daley CL; Koh WJ Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739795 [TBL] [Abstract][Full Text] [Related]